Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 3Recruiting 3Not yet recruiting 3Unknown 2Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 341Ovarian Neoplasms 177Lung Neoplasms 171Breast Neoplasms 118Fallopian Tube Neoplasms 87Neoplasms 79Carcinoma, Ovarian Epithelial 69Squamous Cell Carcinoma of Head and Neck 51Small Cell Lung Carcinoma 49Triple Negative Breast Neoplasms 41Adenocarcinoma of Lung 41Head and Neck Neoplasms 40Neoplasm Metastasis 37Neuroblastoma 34Central Nervous System Neoplasms 33Endometrial Neoplasms 28Esophageal Neoplasms 27Carcinoma 27Brain Neoplasms 27Lymphoma 26Recurrence 25Parkinson Disease 4, Autosomal Dominant Lewy Body 25Lymphoma, Large B-Cell, Diffuse 25Urinary Bladder Neoplasms 24Adenocarcinoma, Bronchiolo-Alveolar 23Testicular Neoplasms 22Astrocytoma 22Melanoma 19Uterine Cervical Neoplasms 18Prostatic Neoplasms 18

Interventions

osimertinib 2Vinorelbine 2Pemetrexed 2Liquid Biopsy 2HMPL-013 2Gefitinib 2Carboplatin 2tislelizumab 1sulindac sulfone 1rezivertinib 1pembrolizumab 1anlotinib 1Radiotherapy 1Platinum 1Paclitaxel 1Gemcitabine 1Cisplatin 1Cetuximab 1CP protocol 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × NSCLC × Carboplatin × Clear all
NCT03562871 2022-04-21

IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC

IO Biotech

Phase 1/2 Completed
109 enrolled
Thoracic

NSCLC

NCT00874848 2016-11-29

Efficacy/Safety of Imprime PGG With Cetuximab & Paclitaxel/Carboplatin Therapy in Pts With Untreated Advanced Non-Small Cell Lung Cancer

HiberCell, Inc.

Phase 2 Completed
90 enrolled 20 charts
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡